Summit Therapeutics Inc

NASDAQ:SMMT   12:15:49 PM EDT
5.21
+0.02 (+0.38%)
Products

Summit Therapeutics Says FDA Doesn't Agree With Change To Primary Endpoint In Ri-CoDIFy Studies

Published: 09/21/2021 20:58 GMT
Summit Therapeutics Inc (SMMT) - Summit Therapeutics - FDA Doesn't Agree With Change to Primary Endpoint Proposed and Implemented in Phase Iii Ri-codify Studies When Combining Studies.
Further Company Coverage: Smmto ((reuters.
Briefs@thomsonreuters.
Com;)).